The PopSeq project is the first ever study to return genomic results (gRoR) in an all African American population cohort and a primarily European American cohort, including participants enrolled in the Jackson and Framingham Heart studies. The goal of this project is to study important gRoR outcomes and how they compare between participants in these two cohorts. Our gRoR design will serve as a resource for other population cohort studies and biobanks planning to return genomic results to their study participants. This study will also inform future efforts to scale the labor-intensive process of variant classification and will explore penetrance among populations unselected for family history.

The Personal Genome Sequencing Outcomes (PeopleSeq) Consortium, funded by the NIH, is one of the first large-scale longitudinal studies to examine the experiences, attitudes and outcomes of apparently healthy adults who have elected to obtain exome or genome sequencing. Data collected will provide valuable information on the potential benefits and costs of performing sequencing in healthy individuals, and key insights into the feasibility of using sequencing to create a more personalized and preventative model of medicine.

The MilSeq Project, funded by the Department of Defense through the Air Force Medical Support Agency, is a pilot study examining the process of incorporating whole exome sequencing (WES) into the United States Air Force (USAF) military health system. Active-duty service members of the USAF (Airmen) are enrolled into the study to undergo clinical WES.

Risk Evaluation and Education of Alzheimer’s Disease: the Study of Communicating Amyloid Neuroimaging (REVEAL-SCAN), funded by the NIH, is the first multi-site, randomized clinical trial to examine the impact of learning amyloid imaging results in cognitively normal individuals.

The MedSeq Project was the first NIH-funded randomized clinical trial to empirically study the use of whole genome sequencing in both a healthy population and a population with suspected genetic cardiac disease. The project was designed to explore the medical, behavioral and economic impacts of incorporating genome sequencing into everyday medicine and was led by a multi-disciplinary team of more than 40 scientists.

The Impact of Personal Genomics (PGen) Study, funded by the NIH, was a survey of consumers from two U.S. companies providing direct-to-consumer genetic testing, using independent third-party data collection and analysis to provide data on who was ordering these tests and why, and potential benefits and risks.

The Risk Evaluation and Education for Alzheimer’s Disease (REVEAL) Study, funded by the NIH, was a series of multi-site randomized controlled clinical trials that provided empirical data to address ethical, social and translational issues in genetic susceptibility testing for common diseases.

The Genomes2Veterans Research Program at the Veterans Affairs (VA) Boston Healthcare System is run by director Jason Vassy, MD, MPH, SM, and bridges the expertise of Genomes2People and the mission of bringing 21st century medical care to Veterans.

The Econogenomics Working Group is a multidisciplinary group of​ investigators from multiple sites around the country with diverse clinical and methods expertise. Led by Kurt Christensen, PhD, the group has clinical expertise in genetics, pediatrics, and internal medicine in addition to methods expertise in genomics, pharmacoepidemiology, simulation modeling, cost-effectiveness, and health systems research.

We have assembled a Genomics & Life Insurance Working Group of experts to explore themes, challenges and benefits of educating life insurers about genetic and genomics concepts.

The Imagenetics METRICS Study, funded by Sanford Health, was launched in 2019 to evaluate the outcomes of the Sanford Chip Program, one of the first genetic tests offered as a clinical service to adult primary care patients in a major U.S. health care system. Lessons from this study will provide critical information about the benefits, risks, and challenges of integrating genetic testing into general patient care.

Precision Population Health aims to bring the power of precision medicine to primary care settings, where it can be used to treat disease or prevent it before it occurs. The initiative combines expertise from Ariadne Labs and Genomes2People, creating a world-class collaboration of clinical genomics experts and implementation scientists to overcome the challenges that primary care providers who seek to adopt precision medicine face.